Navigation Links
Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing

Dan Gold, Ph.D., Joins as Chief Executive Officer

MENLO PARK, Calif., Dec. 10 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB), a privately held biotechnology company, announced the completion of a $21 million Series B financing. Prior investor SV Life Sciences (SVLS) led the round followed by co-lead investor Alta Partners. The proceeds from the financing will be used to develop FAB's novel, cell-free protein synthesis technology to produce biologic drugs and vaccines for unmet medical needs. David Mack, Ph.D., Director at Alta Partners has joined Michael Ross, Ph.D., Managing Partner at SVLS, as a member of the Board of Directors.

Cell-free technology was designed to overcome the limitations of cell-based production of proteins that are often subject to degradation, low yields and purification difficulties, or are not therapeutically effective because of structural deficiencies due to poor folding.

FAB's proprietary cell free protein synthesis technology was developed by James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis. Dr. Swartz holds the Leland T. Edwards Professorship in the School of Engineering at Stanford University and is a Professor in the Departments of Bioengineering and Chemical Engineering. He is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. Dr. Swartz serves on the Board of Directors of the company.

FAB also announced that Daniel Gold, Ph.D. has joined the company as Chief Executive Officer. Dr. Gold has over twenty years of biopharmaceutical process development and manufacturing experience. He joins FAB from Human Genome Sciences (HGS) where he was Senior Vice President, Manufacturing Alliances, and Senior Vice President of Pharmaceutical Operations. Prior to joining HGS, Dr. Gold was Vice President, Process Development and Chief Scientific Officer at Diosynth-RTP, Inc., where he directed the manufacturing of fifteen protein-based therapeutics, leading to IND, BLA or NDA submission and approval. Dr. Gold also held scientific and management positions in process development and manufacturing at Genencor, Genentech and Khepri Pharmaceuticals. Dr. Gold received his Ph.D. and M.S. degrees in Biochemical Engineering from the Massachusetts Institute of Technology.

"The confidence of our investors, Alta Partners and SV Life Sciences, provides further validation for the therapeutic and commercial potential of this unique and exciting technology," said Dr. Gold. "Our goals are both to develop our own propriety products and to collaborate with other biopharmaceutical companies to develop high-quality protein-based drugs. I am happy to join FAB at this exciting time in the company's development."

Dr. Michael Ross stated, "SVLS is pleased to help advance the development of FAB's cell-free technology to bring novel biologics to market for the treatment of unmet medical needs. This groundbreaking approach could provide protein-based drugs and vaccines that are difficult or impossible to synthesize, increasing their therapeutic and commercial viability."

"The current industry standard of cell-based protein synthesis and purification may limit the types of protein drugs than can be made," said Dr. Mack. "FAB's technology focuses on maximizing certain biochemical reactions, eliminating others, while introducing novel pathways. This presents exciting potential for the commercialization of novel protein pharmaceuticals."

About Fundamental Applied Biology

Fundamental Applied Biology (FAB), Inc. is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. FAB's goal is to become the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies that will provide improved clinical outcomes for patients.

About SV Life Sciences

SV Life Sciences is a venture capital firm providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices, and services. SV Life Sciences currently advises or manages five funds -- SV Life Sciences Funds I, II, III and IV and International Biotechnology Trust plc (Ticker: IBT.L) with capital of approximately $1.6 billion.

About Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 120 companies in the sector to date.

SOURCE Fundamental Applied Biology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... and SensoMotoric Instruments (SMI) announce a mobile plug and ... captured during interactive real-world tasks SensoMotoric Instruments ... of their established wearable solutions for eye tracking and ... behavior captured with SMI Eye Tracking Glasses 2w ...
Breaking Biology News(10 mins):